title: [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
abstract: In cardiogenic shock, combined pharmacotherapy with dopamine/dobutamine was being used as a standard regimen and was compared to dopamine/milrinone in this study. In a total of 20 patients with persistent hemodynamic depression despite mechanical ventilation plus dopamine (10-12 micrograms/kg/min) and nitroglycerin (33 micrograms/min) infusions additional therapy with dobutamine (maximal dose: 9 micrograms/kg/min; n = 10) or milrinone (0.5 microgram/kg/min; n = 10) was started. Dobutamine induced an increase of cardiac index (2.0 +/- 0.1 to 2.9 +/- 0.21/min/m2; p < 0.01; mean +/- SEM) and heart rate (96 +/- 6 to 117 +/- 5 min-1; p < 0.05) while mean arterial pressure (75 +/- 2 to 71 +/- 4 mm Hg) and pulmonary capillary wedge pressure (21 +/- 2 to 19 +/- 2 mm Hg) hardly changed. The rate-pressure product rose from 10790 +/- 684 to 13234 +/- 678 mm Hg/ min (p < 0.05). Milrinone had a comparable effect on cardiac index (2.0 +/- 0.1 to 2.6 +/- 0.1 I/min/m2; p < 0.01) but induced a minor change in heart rate (94 +/- 6 to 104 +/- 8 min-1; p < 0.05) and a more pronounced decrease in mean arterial pressure (77 +/- 2 to 65 +/- 2 mm Hg; p < 0.01) and pulmonary capillary wedge pressure (24 +/- 2 to 17 +/- 1 mm Hg; p < 0.01). The rate-pressure product declined (11033 +/- 711 to 10555 +/- 929 mm Hg/min). In comparison, dopamine/milrinone appeared to be advantageous in terms of pre- and afterload reduction and myocardial oxygen demand. However, the concomitant decline in arterial pressure might impair end-organ perfusion.
authors.affiliation: Klinik für Kardiologie, Christian-Albrechts-Universität Kiel.
authors.forename: A
authors.initials: A
authors.lastname: Meissner
authors.forename: T
authors.initials: T
authors.lastname: Schmelzle
authors.forename: R
authors.initials: R
authors.lastname: Simon
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004280:Dobutamine / Q000008:administration & dosage* / Q000009:adverse effects; D004298:Dopamine / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020105:Milrinone; D005996:Nitroglycerin / Q000008:administration & dosage; D011728:Pyridones / Q000008:administration & dosage* / Q000009:adverse effects; D012770:Shock, Cardiogenic / Q000188:drug therapy* / Q000503:physiopathology; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology
chemical_list: D002316:Cardiotonic Agents; D011728:Pyridones; D004280:Dobutamine; D005996:Nitroglycerin; D020105:Milrinone; D004298:Dopamine
vernacular_title: Differentialtherapie des kardiogenen Schocks mit Dopamin/Milrinon im Vergleich zu Dopamin/Dobutamin.